Pioneering the next generation of treatment solutions
We support innovation across the continuum of care, to help to develop new technologies, treatments and vaccines.
-
The new Ebola clinical trial that’s focused on helping halt future outbreaks
A groundbreaking partnership between countries, health organizations and companies worldwide—including Johnson & Johnson—hopes to find the most promising vaccines to help protect people from the virus.
Featured stories
-
-
Janssen Wins Prestigious International Prix Galien Award for MDR-TB Treatment
Ground breaking therapy offers hope for people with Multi-Drug Resistant Tuberculosis (MDR-TB)
More from Johnson & Johnson
-
The science behind targeted oral peptides
A new type of medication is tackling a problem that has long frustrated drug developers: how to deliver peptide therapies orally and hit their target more precisely. -
“Reimagining what life with schizophrenia could look like”
Johnson & Johnson’s Leonardo Diaz, M.D., addresses common misconceptions about schizophrenia, the critical importance of preventing relapse and why there’s so much optimism about treatments. -
A behind-the-scenes look at how Johnson & Johnson manufactures and delivers CAR-T cell therapy for multiple myeloma
Transforming cancer patients’ own cells into a targeted treatment is a complex and nuanced process. Jessica Torfs, director of Global CAR-T Supply Chain at Johnson & Johnson, explains what it takes to deliver this cutting-edge personalized therapy.
